Kesimpta is under clinical development by Novartis and currently in Phase III for Multiple Sclerosis. According to GlobalData, Phase III drugs for Multiple Sclerosis have a 68% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Kesimpta’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ofatumumab (Kesimpta / Bonspri) is a recombinant human monoclonal immunoglobulin G1 (IgG1) antibody produced in a murine NS0 cell line. It is formulated as solution for subcutaneous route of administration. Kesimpta is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
Ofatumumab (Kesimpta) is also under development for the treatment of multiple sclerosis (RMS). It was under development for Neuromyelitis Optica (Devic’s Syndrome)
Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, hematologic diseases, solid tumors, immune disorders, and infections, among others. The company offers generic medicines and biosimilars through Sandoz. Novartis conducts research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR). The company operates through a network of subsidiaries and offices across the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Novartis is headquartered in Basel, Switzerland.
For a complete picture of Kesimpta’s drug-specific PTSR and LoA scores, buy the report here.